Lixte (LIXT) Stock Jumps On Positive Feedback For Lead Drug Candidate
The current trading session has seen a notable upswing of 52.29% in the shares of Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT), currently valued at $3.43. This surge in LIXT stock is ascribed to the acclaim received by the company’s lead drug candidate. Lixte Biotechnology (LIXT) has disclosed the publication of preclinical data in the digital […]